References
- Becker N. Epidemiology of multiple myeloma. Recent Results Cancer Res. 2011;3(1):1–15.
- Mimura N, Hideshima T, Anderson KC. Novel therapeutic strategies for multiple myeloma. Exp Hematol. 2015;43(8):732–741. doi: https://doi.org/10.1016/j.exphem.2015.04.010
- Kuijlen JM, Bremer E, Mooij JJA, et al. Review: on TRAIL for malignant glioma therapy? Neuropathol Appl Neurobiol. 2010;36(3):168–182. doi: https://doi.org/10.1111/j.1365-2990.2010.01069.x
- Jian Y, Chen Y, Geng C, et al. Target and resistance-related proteins of recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand on myeloma cell lines. Biomed Rep. 2016;4(6):723–727. doi: https://doi.org/10.3892/br.2016.650
- Fang F. Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand. Acta Pharmacol Sin. 2005;26(11):1373–1381. doi: https://doi.org/10.1111/j.1745-7254.2005.00206.x
- Lincz LF, Yeh TX, Spencer A. TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy. Leukemia. 2001;15(10):1650–1657. doi: https://doi.org/10.1038/sj.leu.2402251
- Sreedhar AS, Csermely P. Heat shock proteins in the regulation of apoptosis: new strategies in tumor therapy: a comprehensive review. Pharmacol Ther. 2004;101(3):227–257. doi: https://doi.org/10.1016/j.pharmthera.2003.11.004
- Goetz MP. The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol. 2003;14(8):1169–1176. doi: https://doi.org/10.1093/annonc/mdg316
- Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature. 2003;425(6956):407–410. doi: https://doi.org/10.1038/nature01913
- Zsebik B, Citri A, Isola J, et al. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. Immunol Lett. 2006;104(104):146–155. doi: https://doi.org/10.1016/j.imlet.2005.11.018
- Williams CR, Tabios R, Linehan WM, et al. Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model. J Urol. 2007;178(1):1528–1532. doi: https://doi.org/10.1016/j.juro.2007.05.120
- Mitsiades CS. Antimyeloma activity of heat shock protein-90 inhibition. Blood. 2005;107(3):1092–1100. doi: https://doi.org/10.1182/blood-2005-03-1158
- Ma Y. Sensitization of TRAIL-resistant cells by inhibition of heat shock protein 90 with low-dose geldanamycin. Mol Cancer Ther. 2006;5(5):170–178. doi: https://doi.org/10.1158/1535-7163.MCT-05-0129
- Secchiero P, Vaccarezza M, Gonelli A. TNF-related apoptosis-inducing ligand (TRAIL): a potential candidate for combined treatment of hematological malignancies. Curr Pharm Des. 2004;10(29):3673–3681. doi: https://doi.org/10.2174/1381612043382747
- Duiker EW, Mom CH, de Jong S, et al. The clinical trail of TRAIL. Eur J Cancer. 2006;42(14):2233–2240. doi: https://doi.org/10.1016/j.ejca.2006.03.018
- Jin Z, Dicker DT, El-Deiry WS. Deficient tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor transport to the cell surface in human colon cancer cells selected for resistance to TRAIL-induced apoptosis. J Biol Chem. 2004;279(34):35829–35839. doi: https://doi.org/10.1074/jbc.M405538200
- Blum A, Chaperot L, Molens J-P, et al. Mechanisms of TRAIL-induced apoptosis in leukemic plasmacytoid dendritic cells. Exp Hematol. 2006;34(12):1655–1662. doi: https://doi.org/10.1016/j.exphem.2006.08.002
- Safa AR, Day TW, Wu CH. Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy. Curr Cancer Drug Targets. 2008;8(1):37–46. doi: https://doi.org/10.2174/156800908783497087
- Siegelin MD, Gaiser TA. Myricetin sensitizes malignant glioma cells to TRAIL-mediated apoptosis by down-regulation of the short isoform of FLIP and bcl-2. Cancer Lett. 2009;283(2):230–238. doi: https://doi.org/10.1016/j.canlet.2009.04.002
- Wen J, Ramadevi N, Nguyen D, et al. Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. Blood. 2000;96(12):3900–3906.
- Liu Q, Hilsenbeck S, Gazitt Y. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood. 2003;101(10):4078–4087. doi: https://doi.org/10.1182/blood-2002-10-3231
- Balsas P, López-Royuela N, Galán-Malo P, et al. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis. Biochem Pharmacol. 2009;77(5):804–812. doi: https://doi.org/10.1016/j.bcp.2008.11.024
- Yee L, Fanale M, Dimick K, et al. A phase IB safety and pharmacokinetic (PK) study of recombinant human Apo2L/TRAIL in combination with rituximab in patients with low-grade non-Hodgkin lymphoma. J Clin Oncol. 2007;25:8078.
- Duus J, Bahar HI, Venkataraman G, et al. Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma. Leuk Lymphoma. 2006;47(7):1369–1378. doi: https://doi.org/10.1080/10428190500472123
- Hallek M, Neumann C, Schäffer M, et al. Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines. Exp Hematol. 1998;25(13):1367–1377.
- Chaurasia AR. Fertility transition in India – evidence from DLHS 2007-08. J Fam Welfare. 2013;59(1):12–32.